Pull to refresh
Logo
What Changed
Following Why Sign Up
Study of 300 million lab tests finds menopause triggers abrupt body-wide changes

Study of 300 million lab tests finds menopause triggers abrupt body-wide changes

New Capabilities

A deconvolution method aligned blood tests to the final menstrual period, finding 52 of 90 markers jump at menopause in women and none in men

November 2nd, 2026: Separate study links menopause protein shifts to brain aging

Overview

Updated 7 days ago

Menopause has long been treated as a slow shutdown of reproduction. An analysis of 300 million lab tests from women in the United States and Israel found a sharper pattern: 52 of 90 markers jump at the final menstrual period, across bone, liver, kidney, lipid and blood systems. Men showed no such step.

The Nature Medicine paper, published Oct. 1, has drawn both interest and skepticism. A separate study published Nov. 2 linked menopause-related protein changes to brain aging and a modestly higher Alzheimer's risk. Alon cautioned that the hormone-therapy findings are observational, and his lab is planning a randomized trial of treatment started before the final period.

Why it matters

If menopause is a step change, screening and hormone therapy may start years too late to protect bone, metabolic and brain health.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

300 million
Laboratory tests analyzed
Routine lab results spanning the US-NHANES and Israel-Clalit cohorts, 1999 to 2024.
52 of 90
Tests with abrupt jump at menopause in women
Jump sizes ranged from 0.1 to 1.4 standard deviations across endocrine, bone, hepatic, lipid, and blood systems.
1 million+
Women studied
Cross-sectional data from two independent population-scale cohorts.
0.89
Correlation of jump sizes between the two datasets
Israel-Clalit and US-NHANES produced strongly matching results despite different populations and study designs.

Voices

Curated perspectives — historical figures and your fellow readers.

Sign up to generate historical perspectives on this story.

Log in Sign Up

People Involved

Uri Alon
Uri Alon
Professor at Weizmann Institute of Science, lead author of the study
Leading the research team; preparing a randomized trial of pre-menopause hormone therapy
 González (first name not reported)
González (first name not reported)
Spanish gynecologist quoted in EL PAÍS coverage
Commenting on the study's clinical implications

Organizations Involved

Weizmann Institute of Science
Weizmann Institute of Science
Research institute
Host institution for the study's lead author

Israeli research institute where Professor Uri Alon's group developed the deconvolution method and led the analysis.
Nature Medicine
Nature Medicine
Peer-reviewed journal
Published the peer-reviewed study

Monthly medical journal that published the menopause deconvolution study in October 2026.

Timeline

November 2025 November 2026

3 events Latest: November 2nd, 2026 · 1 week ago

  1. Separate study links menopause protein shifts to brain aging

    Latest Research Release

    A Nature Medicine study led by Jacobs found 16 proteins tied to brain aging and dementia risk change across menopause. Higher risk scores were linked to modestly greater Alzheimer's risk in a UK Biobank analysis.

  2. Study published in Nature Medicine

    Publication

    The peer-reviewed paper appears, reporting abrupt jumps in 52 of 90 lab markers at the final menstrual period. Media coverage and expert commentary followed in the next two weeks.

  3. Preprint posted on arXiv

    Research Release

    The deconvolution analysis of 300 million lab tests circulates as an unreviewed preprint under the title about a systemic physiological cliff at menopause.

Scenarios

1

Guidelines shift menopause screening earlier

Possible Resolves by End of 2028

Discussed by: Professor Uri Alon; ABC News; EL PAÍS coverage

If the cliff finding holds, professional bodies could move baseline bone-density screening into the late 30s or 40s and reconsider when menopausal hormone therapy should begin. Alon said checking bone density at 40 or 45, then considering hormone therapy as prevention, would follow from the data.

2

Randomized trial of pre-menopause hormone therapy launches

Likely Resolves by End of 2028

Discussed by: Professor Uri Alon, whose laboratory says it is preparing such a trial

Alon stated his lab is preparing a randomized trial of hormone therapy begun before the final menstrual period, measuring effects on bone and brain health. A registered trial would move the observational finding toward causal evidence and test whether early MHT prevents the cliff rather than repairing damage after it.

3

Findings contested by independent reanalysis

Possible Resolves by End of 2028

Discussed by: Australian experts via Scimex; gynecologist González in EL PAÍS

Critics note the study is retrospective and observational, relying on self-reported menopause information and population averages that may not describe individual women. An independent cohort analysis or a reanalysis using different assumptions could challenge the cliff interpretation or narrow which tests truly jump.

4

Researchers and advocates clash over the 'cliff' label

Possible Resolves by End of 2026

Discussed by: KhanList feature; Australian menopause clinicians quoted by ABC News

A KhanList feature calls the 'cliff' framing 'good marketing, not good biology,' arguing the sudden-change narrative conflicts with the gradual, fluctuating perimenopause many women describe. The dispute turns on language and metaphor, not on the underlying lab data.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

1996 to present

Study of Women's Health Across the Nation (1996)

The U.S. longitudinal SWAN study followed thousands of women through the menopause transition, establishing much of the current framework for how hormones change across perimenopause. It tracked follicle-stimulating hormone, estradiol, and other markers with repeated measurements over decades.

Then

SWAN became the reference standard for describing the menopause transition and its timing in individual women.

Now

Its findings underpin current screening and treatment windows for perimenopausal women.

Why this matters now

The new study, using cross-sectional population data, estimates key hormone shifts begin about seven years earlier than SWAN described — anti-Müllerian hormone falling roughly 15 years before the final period, estradiol about 12 years, and FSH rising about 14 years prior.

1990s to 2002

Women's Health Initiative hormone therapy trial (2002)

The U.S. Women's Health Initiative randomized trial halted its combined estrogen-progestin arm early after finding increased risks of breast cancer and cardiovascular events. The findings dramatically cut hormone therapy use worldwide and reshaped the risk calculus for treating menopause symptoms.

Then

MHT prescriptions fell sharply and prescribing guidance became far more cautious.

Now

Two decades later, MHT remains underused relative to symptom burden, and debates over timing and risk persist.

Why this matters now

The new study reports that women taking hormone therapy showed smaller jumps in 39 of 80 tests, reconnecting the cliff finding to the long-standing MHT risk-benefit debate and the question of when treatment should start.

Sources

(12)
+6
Nature Medicine arXiv ScienceAlert EL PAÍS English ABC News Scimex Ynetnews Earth.com Newswise KhanList The Current, UC Santa Barbara The Jerusalem Post